1. Home
  2. RAVE vs OTLK Comparison

RAVE vs OTLK Comparison

Compare RAVE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

N/A

Current Price

$2.65

Market Cap

40.1M

ML Signal

N/A

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.34

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
OTLK
Founded
1958
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
38.7M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
RAVE
OTLK
Price
$2.65
$0.34
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$2.50
AVG Volume (30 Days)
21.1K
1.1M
Earning Date
05-07-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
55.91
EPS
0.09
N/A
Revenue
$15,120,000.00
$8,146,123.00
Revenue This Year
N/A
$1,726.70
Revenue Next Year
N/A
$80.34
P/E Ratio
$29.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.29
52 Week High
$3.75
$3.39

Technical Indicators

Market Signals
Indicator
RAVE
OTLK
Relative Strength Index (RSI) 38.56 34.70
Support Level $2.34 N/A
Resistance Level $3.21 $0.46
Average True Range (ATR) 0.13 0.04
MACD 0.00 0.00
Stochastic Oscillator 48.65 30.41

Price Performance

Historical Comparison
RAVE
OTLK

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: